Targacept to Host Conference Call Today at 10:00 AM to discuss AstraZeneca Collaboration on TC-5214 for Major Depressive Disorder
Winston-Salem, North Carolina
December 03, 2009
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), announced that Targacept management will conduct a conference call and audio webcast today at 10:00 a.m. Eastern Standard Time regarding the company’s global collaboration with AstraZeneca for late-stage product candidate TC-5214 for the treatment of major depressive disorder which was announced earlier this morning.
The conference call may be accessed by dialing 866-700-7173 for domestic participants and 617-213-8838 for international callers (reference passcode 63585633). A replay of the conference call may be accessed beginning approximately two hours after the event and continuing through December 17, 2009 by dialing 888-286-8010 for domestic callers 617-801-6888 for international callers (reference passcode 39947014).
A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on Targacept’s website for at least two weeks following the call.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders, in support of its vision of building health and restoring independence for patients. Targacept’s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has clinical-stage product candidates in development for major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer's disease and cognitive dysfunction in schizophrenia, as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept’s news releases are available on its website at www.targacept.com.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Tel: 336-480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Tel: 508-362-3087
Email: linnmich@comcast.net
Back to Newsroom